Juncture Wealth Strategies LLC Sells 1,116 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Juncture Wealth Strategies LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,282 shares of the company’s stock after selling 1,116 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Neurocrine Biosciences were worth $994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Brooklyn Investment Group lifted its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after buying an additional 115 shares during the period. Blue Trust Inc. lifted its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the period. UMB Bank n.a. lifted its stake in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after acquiring an additional 309 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Neurocrine Biosciences by 42.0% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after acquiring an additional 157 shares in the last quarter. Finally, Truvestments Capital LLC purchased a new position in Neurocrine Biosciences during the 3rd quarter valued at $63,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Barclays lifted their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. Piper Sandler reissued an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $165.40.

Neurocrine Biosciences Stock Up 0.8 %

Shares of NASDAQ NBIX opened at $148.73 on Friday. The company has a 50 day moving average of $134.09 and a 200 day moving average of $131.38. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The firm has a market cap of $15.06 billion, a P/E ratio of 39.87 and a beta of 0.33.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at $346,216.70. This represents a 9.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,694 shares of company stock worth $9,676,730 over the last quarter. 4.30% of the stock is currently owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.